JP2009508532A5 - - Google Patents

Download PDF

Info

Publication number
JP2009508532A5
JP2009508532A5 JP2008532384A JP2008532384A JP2009508532A5 JP 2009508532 A5 JP2009508532 A5 JP 2009508532A5 JP 2008532384 A JP2008532384 A JP 2008532384A JP 2008532384 A JP2008532384 A JP 2008532384A JP 2009508532 A5 JP2009508532 A5 JP 2009508532A5
Authority
JP
Japan
Prior art keywords
compound
disease
ser
asn
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/036830 external-priority patent/WO2007035872A2/en
Publication of JP2009508532A publication Critical patent/JP2009508532A/ja
Publication of JP2009508532A5 publication Critical patent/JP2009508532A5/ja
Pending legal-status Critical Current

Links

JP2008532384A 2005-09-20 2006-09-20 Tdf関連化合物およびその類似体 Pending JP2009508532A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71901405P 2005-09-20 2005-09-20
PCT/US2006/036830 WO2007035872A2 (en) 2005-09-20 2006-09-20 Tdf-related compounds and analogs thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012073369A Division JP2012149081A (ja) 2005-09-20 2012-03-28 Tdf関連化合物およびその類似体

Publications (2)

Publication Number Publication Date
JP2009508532A JP2009508532A (ja) 2009-03-05
JP2009508532A5 true JP2009508532A5 (enExample) 2011-02-24

Family

ID=37889535

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008532384A Pending JP2009508532A (ja) 2005-09-20 2006-09-20 Tdf関連化合物およびその類似体
JP2012073369A Withdrawn JP2012149081A (ja) 2005-09-20 2012-03-28 Tdf関連化合物およびその類似体
JP2014010456A Pending JP2014132900A (ja) 2005-09-20 2014-01-23 Tdf関連化合物およびその類似体
JP2015206139A Pending JP2016047829A (ja) 2005-09-20 2015-10-20 Tdf関連化合物およびその類似体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012073369A Withdrawn JP2012149081A (ja) 2005-09-20 2012-03-28 Tdf関連化合物およびその類似体
JP2014010456A Pending JP2014132900A (ja) 2005-09-20 2014-01-23 Tdf関連化合物およびその類似体
JP2015206139A Pending JP2016047829A (ja) 2005-09-20 2015-10-20 Tdf関連化合物およびその類似体

Country Status (13)

Country Link
US (3) US8299212B2 (enExample)
EP (3) EP2927241A1 (enExample)
JP (4) JP2009508532A (enExample)
AU (1) AU2006292147B2 (enExample)
CA (2) CA2623415A1 (enExample)
CY (1) CY1116742T1 (enExample)
DK (1) DK2497780T3 (enExample)
ES (1) ES2537527T3 (enExample)
HU (1) HUE026634T2 (enExample)
PL (1) PL2497780T3 (enExample)
PT (1) PT2497780E (enExample)
SI (1) SI2497780T1 (enExample)
WO (1) WO2007035872A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
US8995742B1 (en) * 2009-11-10 2015-03-31 Us Synthetic Corporation Systems and methods for evaluation of a superabrasive material
CA2842330A1 (en) * 2011-07-19 2013-01-24 Thrasos Innovation, Inc. Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis
ES3012536T3 (en) * 2012-08-03 2025-04-09 Dana Farber Cancer Inst Inc Antibody against repulsive guidance molecule b (rgmb)
WO2015164800A2 (en) * 2014-04-24 2015-10-29 University Of Central Florida Research Foundation, Inc. Compositions and methods for modulating polarization of monocytes
WO2016077539A1 (en) * 2014-11-12 2016-05-19 Thrasos Innovation, Inc. Peptides with enhanced stability and their use in methods for treating diseases
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
EP4595974A3 (en) 2018-10-22 2025-08-13 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use
CA3212468A1 (en) * 2021-03-16 2022-09-22 William D. Carlson Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis
EP4404950A4 (en) * 2021-09-22 2025-06-18 Therapeutics by Design, LLC CANCER TREATMENT METHODS
KR102749109B1 (ko) * 2021-11-04 2025-01-03 (주)케어젠 생리 활성을 갖는 펩타이드 및 그의 용도
WO2024081245A1 (en) 2022-10-10 2024-04-18 Therapeutics By Design, LLC Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury
CN120838344B (zh) * 2025-09-19 2025-11-28 安徽天铁锂电新能源有限公司 粗碳酸锂提纯电池级碳酸锂的装置及其提纯方法

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4768523A (en) 1981-04-29 1988-09-06 Lifecore Biomedical, Inc. Hydrogel adhesive
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP2874751B2 (ja) 1986-04-09 1999-03-24 ジェンザイム・コーポレーション 希望する蛋白質をミルク中へ分泌する遺伝子移植動物
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
GB8630273D0 (en) 1986-12-18 1987-01-28 Til Medical Ltd Pharmaceutical delivery systems
US5041126A (en) 1987-03-13 1991-08-20 Cook Incorporated Endovascular stent and delivery system
US5092871A (en) 1987-03-13 1992-03-03 Brown University Research Foundation Electrically-charged nerve guidance channels
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5213580A (en) 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4955892A (en) 1988-10-24 1990-09-11 Louisiana State University Neural cell adhesion protein nerve prosthesis
US5089606A (en) 1989-01-24 1992-02-18 Minnesota Mining And Manufacturing Company Water-insoluble polysaccharide hydrogel foam for medical applications
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH085780B2 (ja) 1989-04-28 1996-01-24 呉羽化学工業株式会社 変形性関節症治療剤
DE69033493D1 (de) 1989-07-25 2004-08-12 Cell Genesys Inc Homologe rekombination für universelle donorzellen und chimerische säugetierzellen
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
US5052998A (en) 1990-04-04 1991-10-01 Zimmon David S Indwelling stent and method of use
US5064435A (en) 1990-06-28 1991-11-12 Schneider (Usa) Inc. Self-expanding prosthesis having stable axial length
IL98764A0 (en) 1990-07-10 1992-07-15 Smithkline Beecham Corp Oxamides
AU1570292A (en) 1991-02-07 1992-09-07 Board Of Trustees Of The University Of Illinois, The Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
DE69231946T2 (de) 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
US5147370A (en) 1991-06-12 1992-09-15 Mcnamara Thomas O Nitinol stent for hollow body conduits
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
JP3693338B2 (ja) 1991-08-30 2005-09-07 キュリス インコーポレイテッド 組織形成因子誘導による炎症反応の調節
ES2253736T3 (es) 1991-08-30 2006-06-01 Curis, Inc. Tratamiento para prevenir la perdida y/o aumentar la masa osea en transtornos metabolicos del hueso.
US5525519A (en) 1992-01-07 1996-06-11 Middlesex Sciences, Inc. Method for isolating biomolecules from a biological sample with linear polymers
US5176626A (en) 1992-01-15 1993-01-05 Wilson-Cook Medical, Inc. Indwelling stent
US5683448A (en) 1992-02-21 1997-11-04 Boston Scientific Technology, Inc. Intraluminal stent and graft
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
AU682154B2 (en) 1992-09-15 1997-09-25 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
AU681356B2 (en) 1992-09-16 1997-08-28 Stryker Corporation Morphogen-induced liver regeneration
DE69333366T2 (de) 1992-10-30 2004-09-16 The General Hospital Corp., Boston Ein neues zellzyklus kontrollprotein
AU683431B2 (en) 1992-11-17 1997-11-13 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use
US5637480A (en) 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
US5579591A (en) 1993-06-29 1996-12-03 Limited Responsibility Company Frontier Footwear for patients of osteoarthritis of the knee
CA2179029C (en) 1993-12-30 2009-02-24 Philip W. Ingham Vertebrate embryonic pattern-inducing hedgehog-like proteins
ATE378407T1 (de) 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
US5614609A (en) 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
US6306622B1 (en) 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6210899B1 (en) 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5681274A (en) 1995-03-31 1997-10-28 Boston Scientific Corporation Variable length uretheral stent
US5569676A (en) 1995-05-24 1996-10-29 Diehl; Harry W. Method for the treatment of osteoarthritis
WO1997007135A2 (en) 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof
US5989827A (en) 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
JP2000501744A (ja) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ,インコーポレーテッド モルホゲン類似体およびその製法
US6214796B1 (en) 1996-03-22 2001-04-10 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
CA2283356C (en) 1997-03-07 2009-06-30 Mount Sinai Hospital Methods to diagnose a required regulation of trophoblast invasion
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6198281B1 (en) 1997-11-12 2001-03-06 The Research Foundation Of State University Of New York NMR spectroscopy of large proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP3561738B2 (ja) 1998-06-02 2004-09-02 株式会社リガク Bragg反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム
CA2336220A1 (en) 1998-07-24 2000-02-03 The Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-.beta. family of growth factors
JP2002524528A (ja) 1998-09-11 2002-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法
US6329184B1 (en) 1998-12-18 2001-12-11 Pharmacia & Upjohn Ab Crystalline form of activated tartrate-resistant and purple acid phosphatase
US6444802B1 (en) 1999-09-30 2002-09-03 Millenium Pharmaceuticals, Inc. Human aminopeptidase
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6468346B2 (en) 1999-12-10 2002-10-22 Bsi Proteomics Corporation Applying x-ray topography and diffractometry to improve protein crystal growth
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
US6669722B2 (en) 2000-09-22 2003-12-30 Cordis Corporation Stent with optimal strength and radiopacity characteristics
EP1334442A2 (en) 2000-11-06 2003-08-13 Thrasos, Inc. Computer method and apparatus for classifying objects
DE60033576T2 (de) 2000-11-06 2007-10-31 Thrasos, Inc., Waltham Methoden zum screening knochenmorphogenetishemimetika
US20040031066A9 (en) 2001-01-18 2004-02-12 Faustman Denise L. Mouse model for rheumatoid arthritis
US6679911B2 (en) 2001-03-01 2004-01-20 Cordis Corporation Flexible stent
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
US6673106B2 (en) 2001-06-14 2004-01-06 Cordis Neurovascular, Inc. Intravascular stent device
US20030103959A1 (en) 2001-06-22 2003-06-05 Hughes Paul E. Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor
WO2003106972A2 (en) * 2002-06-17 2003-12-24 Thrasos, Inc. Multiple domain tdf-related compounds and analogs thereof
ES2397327T3 (es) * 2002-06-17 2013-03-06 Thrasos, Inc. Compuestos asociados a un dominio único de TDF y análogos de los mismos
AU2005265098B2 (en) * 2004-06-17 2012-02-23 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414093D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
HUE026634T2 (en) * 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Similar Documents

Publication Publication Date Title
JP2012019788A5 (enExample)
JP2014132900A5 (enExample)
JP2012149081A5 (enExample)
JP2010501163A5 (enExample)
US11285149B2 (en) Enhanced immunotherapy of cancer using targeted transcriptional modulators
EP1554309A2 (en) Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics
JP2021518745A (ja) アクチビンiib型受容体変異体およびそれらの使用方法
EA026129B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ ЧЕЛОВЕКА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С β-КЛОТО, РЕЦЕПТОРАМИ FGF И ИХ КОМПЛЕКСАМИ
EA015589B1 (ru) Антитела против миостатина и их применение
AU2016201712A1 (en) ActRIIb antagonists and dosing and uses thereof
EA014112B1 (ru) Моноклональное антитело к миостатину и способы его применения
BR112015005466B1 (pt) Polipeptídeo e seu uso, composição farmacêutica e seu uso, molécula de ácido nucleico isolada, célula hospedeira, e método de detecção ou medição da miostatina em uma amostra
JP2009508532A5 (enExample)
US20180148499A1 (en) Antibody Therapy for Amyloid Beta Disease
JP2025134707A (ja) 血液腫瘍を治療するための遺伝子操作しているγδ-T細胞及び遺伝子操作していないγδ-T細胞に関する組成物及び方法
KR102701695B1 (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
JP2007536212A (ja) レプチンアンタゴニストおよびレプチン定量測定方法
JP7679298B2 (ja) 固形腫瘍を治療するための遺伝子操作しているγδ-T細胞及び遺伝子操作していないγδ-T細胞に関する組成物及び方法
CN105085679B (zh) 全人源抗rankl抗体
JPH10511936A (ja) ヒトソマトスタチン様受容体
JP5685774B2 (ja) メラノコルチン−4受容体に対するモノクローナル抗体およびその結合断片と、悪液質および関連病状および疾患の治療におけるそれらの使用
JP2016511275A (ja) 成長ホルモン化合物
KR20020059331A (ko) 니코틴성 아세틸콜린 수용체
CN116059348A (zh) 基于nkg2d的细胞接合器分子在清除衰老细胞中的应用
WO2022087426A1 (en) Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof